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RESEARCH ARTICLES
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Objective. Determine the effectiveness of TIMER (Tool to Improve Medications in the Elderly via
Review) in helping pharmacists and pharmacy students identify drug-related problems during patient
medication reviews.
Methods. In a randomized, controlled study design, geriatric patient cases were sent to 136 pharma-
cists and 108 third-year pharmacy students who were asked to identify drug related-problems (DRPs)
with and without using TIMER.
Results. Pharmacists identified more tool-related DRPs using TIMER (p5 0.027). Pharmacy students
identified more tool-related DRPs using TIMER in the first case (p 5 0.02), but not in the second.
Conclusion. TIMER increased the number of DRPs identified by practicing pharmacists and pharmacy
students during medication reviews of hypothetical patient cases.
Keywords: medication therapy management, drug-related problems, elderly, community pharmacy
INTRODUCTION
Medicare Part D requiresMTM for enrollees who use
a high proportion of financial resources in the program.1
Pharmacists are challenged to findways to effectively and
efficiently provide MTM services, given the high volume
of prescriptions that they dispense. While there are MTM
plans that assist pharmacists, these services are not always
available.2-3 Community pharmacists, who fill the vast
majority of prescriptions, are in a unique position to pro-
vide important medication reviews.4-6 AnMTM tool may
provide pharmacists with a systematic approach for con-
ducting medication reviews and improve efficiency.
MTM services can be especially valuable to older
adults.7-8 The presence of polypharmacy and age-related
physiological changes cause this population to experience
more drug-related problems (DRPs).9 Medication errors
consist of overuse, underuse, andmisuse, and lead tomore
than 5% of hospital admissions in older adults.9-11 Be-
tween 14% and 23% of older adults receive a medication
that should not have been prescribed for them,12-14 and
10% to 25% of patients have an adverse drug reaction or
adverse drug event.15,16 However, somemedications, such
as statins and angiotensin-converting enzyme (ACE) in-
hibitors, are under prescribed among older adults.17-21
In order to simplify medication reviews, screening
tools have been developed.Available tools includeBeer’s
list, Assessing Care of Vulnerable Elders guidelines, and
the Medication Appropriateness Index.22-28 These tools
can rarely accommodate patients with multiple chronic
diseases, multiple drug interactions, and/or organ-system
insufficiency that may cause patient-specific medication
problems. Medication reviews need to be done in a way
that encompasses the whole patient, not just a particular
disease, medication, or drug interaction. This complexity
makes it nearly impossible to create a tool that is suffi-
ciently specific and sensitive to identify drug therapy
problems.28
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In addition to practicing pharmacists, pharmacy stu-
dents are trained to provide MTM,29,30 but there is cur-
rently no standardized approach used to provide MTM
services or to identify DRPs.31,32 A tool may make the
task of learning how to provide these services easier for
pharmacy students and practicing pharmacists who are
new to MTM. Having such a tool may also facilitate
and improve the efficiency of identifying DRPs.
The objective of this studywas to evaluate the Tool to
Improve Medications in Elderly via Review (TIMER),
a systematic approach to conducting medication reviews
and improving pharmacists’ ability to identify important
drug-related problems among older adults. The specific
aim of this 2-part study was to compare the number and
types of drug-related problems identified by practicing
pharmacists (part 1) and pharmacy students (part 2) with
and without using the TIMER.
METHODS
Development of the TIMER
TIMER is a guide for pharmacists and pharmacy stu-
dents to follow when conducting medication reviews.
TIMER was developed by 2 of the authors (KF and
EC), with input from a consensus panel of 4 regional
experts who reviewed the tool and provided feedback.
Using a scale ranging from strongly agree to strongly
disagree, reviewers rated each section of the TIMER on
whether the content was evidence-based, important, help-
ful/useful, and understandable. Feedback from reviewers
resulted in several improvements to TIMER, for example,
including drug-drug interactions based on both preva-
lence and severity rather than just on severity, and reduc-
ing the symptom timeframe to several months.
An important assumption made in developing
TIMER was that its users have conducted a patient med-
ication history so that a complete medication list is avail-
able. TIMER has 4 sections including cost-effective drug
selection, adherence, medication safety, and attaining
therapeutic goals, and covers the most common medica-
tion issues that affect older adults. Specific reference to
the 8 DRPs commonly used in practice-based research
studies was not included because TIMER was intended
to encourage pharmacists to look beyond those DRPs
and consider patients’ symptomatology and complica-
tions among older adults.
Each of the 4 sections includes points to discuss with
patients and suggested recommendations if a DRP is
found. The section on cost-effective drug selection sug-
gests generic and therapeutic substitution to ensure that
patients are getting the most cost-effective medications.
The section of adherence gives examples of how to ques-
tion patients about adherence and provides specific rec-
ommendations. A section on medication safety addresses
adverse drug effects, screening for symptomology, inap-
propriate medications, drug interactions, and Beer’s cri-
teriamedications.When determiningwhether patients are
attaining their therapeutic goals, TIMER contains guid-
ance on cardiovascular risk reduction and complication
management. The section on cardiovascular riskmanage-
ment outlines the major risk factors for coronary heart
disease and evaluates treatment goals. The section on
complication management identifies common compli-
cations seen in the geriatric population, how to screen
for them, and recommendations for each complication
(Appendix 1).
Evaluation of TIMER Via Written Cases
To evaluate TIMER, a 2-part randomized, controlled
study was designed that involved practicing pharmacists
and pharmacy students using the tool to assess hypothet-
ical patient cases.
Patient Case 1 was developed by one of the authors
(MA) and based on a case taken from IowaTeach, a Uni-
versity resource for faculty members to use in developing
teaching activities. Both clinical and hypothetical patient
cases are available in IowaTeach and many contain addi-
tional instructional materials such as test questions and
teaching notes. Case 1 was an older adult presenting to
a community pharmacist for MTM services. Two expert
clinicians reviewed Case 1 and identified 13 DRPs, 6 of
which were tool-related and 7 that were non-tool-related
(Table 1). Tool-related DRPs were those covered in
TIMER and non-tool-related DRPs were problems not
included in TIMER.The non-tool-related DRPs identi-
fied by the experts were not eliminated from the case
but were not expected to be affected because TIMER
did not contain them.
Cases 2 and 3 were written by 2 of the authors
(MC and JR). Both cases involved older adults present-
ing to pharmacists for MTM services. The authors
identified 4 non-tool-related DRPs and 5 tool-related
DRPs in their respective case, and this list later served
as the key when coding DRPs (Table 1). Case 1 from
the pharmacists study served as the basis for cases 2 and
3. The DRPs from case 1 were incorporated into cases
2 and 3, with substitution of medications. For example,
warfarin interactions in cases 1 and 2 involved levo-
thryoxin, while warfarin interactions in case 3 were
caused by bismuth subsalicylate. Another example
of modifications was the wrong drug used in the cases.
In cases 1 and 2, the wrong drug was propoxyphene and
in case 3 it was diphenhydrame: both are Beer’s list
drugs.
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Part 1: Pharmacists’ Use of the TIMER
A randomized controlled study of practicing pharma-
cists who were members of a regional MTM network
(Iowa, Minnesota, Nebraska, North Dakota, South Da-
kota, Wyoming and Montana) was conducted and half
of the pharmacists were randomly selected to receive
TIMER. All pharmacists received a printed copy of case
1 and a response form with instructions to identify DRPs
in the patient case and write SOAP notes including rec-
ommendations. A document of consent to participate was
also included in the packet. Participants were asked to
return all materials to the investigators and by doing so
indicated their informed consent. IRB approval for this
study was obtained.
The packet of materials was mailed to 136 pharma-
cists in mid-April 2007 and a follow-up postcard was sent
to non-responders 2weeks later. A second packet with the
same materials was mailed again in mid-June to nonres-
ponders and a follow-up postcard was sent 1 month later.
Responses obtained by mid-August 2007 were included
in the analysis. Demographic information obtained when
theMTMnetworkwas formedwas linked to the responses
in this study. These data included age, practice years,
gender, average hours spent in pharmacy per week, and
state in which they practiced.
An investigator (AS) coded the pharmacists’ re-
sponses as either correctly identifying each of the 13
DRPs or not, using a pre-established set of coding rules.
Only the DRPs were considered when coding the
responses, and not the actions the pharmacist recommen-
ded. If a DRPwas unclear, the study team reviewed it and
consensus was reached. The data were entered into
Table 1. Drug-related Problems (DRPs) in Three Cases Evaluating TIMER
DRPs for Case 1 (Part 1):
d Dose too low: LDL not at goal with current dose of Lipitor (T)
d Wrong drug: propoxyphene in elderly (T)
d Needs additional therapy: pain not controlled (T)
d Inappropriate adherence: Norvasc (T)
d Inappropriate adherence: KCl (T)
d Drug interaction: warfarin and levothyroxine (T)
d Possible drug interaction: calcium and levothyroxine based on administration
d Wrong drug: Prilosec for lactose intolerance
d Wrong drug: calcium carbonate vs calcium citrate when taken with PPI
d Needs additional therapy: obesity
d Wrong drug: Norvasc for diabetic hypertension
d Possible additional therapy needed: TSH levels need to be checked
d Dose too high: calcium 1000mg in one dose
DRPs for Case 2 (Part 2):
d Drug interaction: warfarin and levothyroxine (T)
d Inappropriate adherence: verapamil (T)
d Wrong drug: propoxyphene in elderly (T)
d Wrong drug: verapamil for diabetic hypertension (T)
d Dose too low: LDL not at goal with current dose of Lipitor (T)
d Wrong drug: Prilosec for lactose intolerance
d Dose too high: calcium 1000mg in one dose
d Needs additional therapy: obesity
d Possible wrong drug: metformin with reduced renal clearance
DRPs for Case 3 (Part 2):
d Dose too low: warfarin, IRN not at goal
d Adverse drug reaction: citalopram may be causing gastrointestinal side effects
d Adverse drug reaction: terazosin may be causing orthostatic hypotension
d Wrong drug: diphenhydramine in elderly (T)
d Inappropriate adherence: finesteride (T)
d Needs additional therapy: LDL not at goal with pravastatin (T)
d Drug interaction: warfarin and Pepto-Bismol (T)
d Theraputic conversion: generic less costly than Atacand (T)
d Unnecessary drug therapy: saw palmetto not effective
Abbreviations: TIMER 5 Tool to Improve Medications in the Elderly via Review; (T) 5 Tool-related DRP. A Tool-related DRP is one that is
included in TIMER.
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a spreadsheet and analyzed using SPSS. The 2 groups of
pharmacists (those who received the TIMER and those
who did not) were compared for age, years in practice,
and hours worked per week using t tests, and for gender
using the chi-square test. The numbers of tool-related
and non-tool-relatedDRPswere summed for each respon-
dent. The total number of tool-related and non-tool-
related DRPs identified per study group were compared,
controlling for gender and practice years. A chi-square
test also was used to compare each tool-related DRP
identified with whether the pharmacist had received the
TIMER.
Part 2: Pharmacy Students’ Use of the TIMER
In the second part of the study, third-year pharmacy
students enrolled in the Pharmacy Practice Laboratory
course at University of Iowa College of Pharmacy were
asked to identify DRPs in 2 cases, 1 using and 1 not using
TIMER. IRB approval for this study was obtained. As
seating was randomly assigned at the start of the course,
students were already assigned to 54 groups of 2. Students
were informed that their answers would not affect their
grade for the course. Students reviewed a study informa-
tion sheet containing all elements of informed consent.
Their submission of answers indicated informed consent.
For the first 30 minutes of class time, each group of 2 stu-
dents was assigned 1 of 2 patient cases and asked to iden-
tify drug-related problems. For the next 30 minutes, each
groupwas given a second case alongwith the TIMER and
again asked to identify DRPs. Groups of 2 were randomly
assigned to receipt of TIMER for 1 of the 2 cases.
The students were asked to provide their age, phar-
macy grade point average (GPA), gender, laboratory sec-
tion, and a unique identifier, which allowed for statistical
comparisons to be made later without compromising stu-
dents’ anonymity. Groups of 2 students were asked to list
all DRPS that they could find in 30 minutes and state the
action that would be taken for each DRP. As the objective
was to determine whether TIMER improved students’
ability to identify DRPs, only the DRPs were considered
during coding and not students’ proposed solutions.
Coding of responseswas done by an investigator (SL)
trained to examine the SOAP notes and identify the pres-
ence or absence of the DRPs. Each DRP was coded as
either correctly identified or not correctly identified for
each group. A set of coding rules for each case was de-
veloped by the investigator and reviewed by other inves-
tigators before coding was completed. The classification
of a correct versus incorrect DRP was based on their
written identification of a DRP, not necessarily how the
student described it. For example, for the presence of
nonadherence to verapamil in case 2, anymention of poor
compliance with verapamil was coded as a ‘‘yes, the DRP
was identified’’ whether the cause of noncompliance was
attributed to side effect, inability to swallow, or patient
thinking the drug did not work. Also, if poor compliance
with another drug besides verapamil was identified, sub-
jects were not given credit for identifying noncompliance
with verapamil. Simply identifying theADRof verapamil
and constipation was not sufficient if compliance or pa-
tient education was not mentioned. Proposed actions or
recommendations were not used to determine DRPs—the
DRP had to be stated. If a DRP was unclear, the study
team reviewed it and consensus was reached.
Results were entered into a spreadsheet and analyzed
using SPSS. Subjects were divided into 2 study groups:
those who received case 2 first and those who received
case 3 first. Age, gender, and GPA of the student pharma-
cists in the 2 study groups were analyzed using chi-square
and t tests. The number of tool and non-tool related DRPs
identified by student groups were summed across both
cases and used as dependent variables. Tool-relatedDRPs
were those that were included in TIMER. The indepen-
dent variables used in analyses were laboratory section
of the student, whether TIMER was used, and patient
case. A one-way ANOVA was used to calculate the dif-
ference in dependent variables between the 3 Pharmacy
Practice Laboratory sections. Then the effect of TIMER
and case on total tool-related and total non-tool-related
DRPs identifiedwas examined using 2-wayANOVA.We
also analyzed the cases separately for significance of
TIMER using 2-tailed t tests, as case was significant in
the primary analysis. A p value ,0.05 was considered
significant.
RESULTS
Eighty-seven of the 136 practicing pharmacists par-
ticipated in the study. Of these, 41 had been given the
TIMER and 46 had not. The average age of participants
was 37.06 10.6 years; average time in practice was 13.0
6 11.2 years; hours worked per week were 36.3 6 11.2
hours, and 63.2% were female. There were no significant
demographic differences between the 2 groups of phar-
macists. Practice years and age were correlated (0.965),
so age was not included in any further analyses.
The average tool-related DRPs identified by the
respondents was 3.4 6 1.0 by those using the TIMER
and 3.06 1.0 for those not using the TIMER (t5 2.26,
p 5 0.027). The overall model predicting tool-related
DRPs using practice years, gender, and TIMER use was
significant (F5 6.53, p5 0.001). Gender and TIMER use
were significant (p 5 0.007 for both), while number of
practice years was not significant (p 5 0.44). There was
no significant difference in the number of DRPs identified
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by pharmacists in Iowa compared to those in other states
(p 5 0.23). Both use of TIMER and practice years were
associated with the number of non-tool-related DRPs
identified (p5 0.027 and p5 0.030, respectively). When
individual tool-related DRPs were analyzed according
to use of TIMER, none showed a significant difference
(Figure 1).
In part 2 of the study, the average age of the pharmacy
students was 256 4.2 years; average GPAwas 3.36 0.4;
and 57.5%were female. There were no significant differ-
ences in demographics between the 2 groups of students.
The average number of tool-related DRPs identified
by the pharmacy students was 3.306 1.05 using TIMER
and 2.966 1.13 not using TIMER (p5 0.11). Therewas no
significant difference in the number of DRPs identified by
laboratory section (p5 0.31). The overall 2-way ANOVA
model predicting tool-related DRPs using TIMER and case
was significant (p , 0.001). Case was significant (p ,
0.001), but use of TIMER (p 5 0.07) and the interaction
were not significant (p5 0.12). When the effect of TIMER
for each case was examined separately, the number of tool-
related DRPs identified was significantly different for case
2 (p, 0.001, Table 2). Finally, the effect of TIMERon each
tool-related DRP was examined. Only the DRP involving
Beers’ list medications in case 2 showed a significant dif-
ference with use of TIMER (Figure 2).
DISCUSSION
In this randomized study, practicing pharmacists
who used TIMER were able to identify more DRPs than
practicing pharmacists given the same patient case but
not TIMER. TIMER may be helpful to pharmacists be-
cause it provides a structured way of reviewing patients’
profile and medications. Importantly, it may identify
Figure 1. Pharmacists’ Identification of Individual Tool-Related DRPs by Use of TIMER (Tool to Improve Medications in the
Elderly via Review)
Table 2. Average Number of Tool-related and Non-tool-related Drug-Related Problems (DRPs) Identified by Pharmacy Students
by Case
TIMER Used? No. DRPs Identified, No. (SD) P
Case 2 Tool-related DRPs No 26 3.7 (0.8) 0.85
Yes 27 3.8 (0.9)
Case 2 non-Tool-related DRPs No 26 1.8 (0.9) 0.37
Yes 27 2.1 (1.2)
Case 3 Tool-related DRPs No 27 2.2 (0.0) 0.02
Yes 26 2.8 (0.9)
Case 3 non-Tool-related DRPs No 27 2.5 (0.8) 0.12
Yes 26 2.9 (0.9)
Abbreviations: TIMER 5 Tool to Improve Medication in Elderly via Review
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DRPs that pharmacists otherwise would not have consid-
ered, such as Beer’s List medications or new symptoms
attributable to adverse drug events. TIMERalso increased
the number of non-tool-related DRPs identified by pharma-
cists. TIMER appeared to increase DRPs where phar-
macists were less likely to identify problems, namely
unintended adherence, warfarin interactions, and Beer’s list
drugs – although these were identified by less than 50% of
pharmacists.
In part 2 of the study, pharmacy students identified
nearly half of the tool-related DRPs in the patient cases
without using TIMER. This may have occurred because
students were given the case to complete at their labora-
tory workstations where they had a vast number of refer-
ence texts and online resources available to them.
Students also had uninterrupted time in class to complete
the cases. However, pharmacy students appeared less
likely to identify warfarin interactions, nonadherence,
and less costly therapy when TIMER was not used.
In the analysis for pharmacy students, the use of
TIMER was not significant, but analysis by case indi-
cated that TIMER increased the number of DRPs iden-
tified in case 2. The differences in the effects of TIMER
on the 2 cases were probably due to the differences in the
authors of the cases. Although the authors of each case
reviewed both cases to ensure they contained similar
numbers and types of DRPs, the author of case 1 has
been an instructor for 12 years and had written cases
for examinations as well as laboratory activities, while
the author of case 2 had been an instructor for 1 year. The
author having less experience writing cases may have
made the DRPs in the first case ‘‘easier’’ for students
to find, and having 2 different authors write the cases
may be a limitation of this study. Yet, given that each
case had a randomized control group for comparison
strengthens the findings.
In 2 of the 3 patient cases used in this study, the
number ofDRPs identified by subjects increased. The fact
that 3 different cases were used in this study increases the
generalizability of the findings because findings are not
limited to 1 set of drug-related problems or 1 type of
patient care. TIMER may be more useful in some
patients’ cases than others, as indicated by the results from
pharmacy students. There was no single DRP that seemed
more easily identifiable using TIMER.
The content validity of TIMER was established by
experts who practice in geriatrics or family medicine.
TIMER could be improved by including other DRPs typ-
ically identified by pharmacists such as high/low dose,
ensuring an existing indication for all medications, and
considering whether all indications are treated. However,
we sought to include DRPs beyond those traditionally
used by pharmacists. There are a number of companies
that have createdMTMplans or systems that prompt phar-
macists when a DRP or problem is detected. These pro-
grams prompt pharmacists when anMTM service needs to
be performed for a specific reason.1,2 Typically, these
prompts are generated from prescription claims analyses,
Figure 2. Student Pharmacists’ Identification of Individual Tool-Related DRPs by Use of TIMER (Tool to Improve Medications
in the Elderly via Review)
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and we assert that pharmacists need to look at the entire
patient when performing MTM. This reasoning was crit-
ical to the inclusion of a symptomology assessment in
TIMER. It guides pharmacists through a broader review
of patients and may serve as an added tool to any of these
programs.
In order to use TIMER in practice, pharmacists may
require training. We did not provide any training to par-
ticipants in this study. Training could consist of how to
read TIMER, how to apply it to individual patients, and
how to examine each patient differently while using it.
This might consist of a 30-minute session with an inves-
tigator, or a training program in print or online. TIMER
also requires regular updates to reflect new guidelines,
medications, and evidence.
Limitations
There are limitations to this study. Although the cases
used were representative of typical cases seen in practice,
TIMER has not been tested with actual patients. Recom-
mendations made by pharmacists or pharmacy students
were not included, and these are important in resolving
DRPs. Also, how TIMER may affect the efficiency of
providing an MTM service was not tested. Additionally,
3 different case writers were used, but cases 2 and 3 were
based on case 1 and the latter 2 cases were each reviewed
by 2 of the investigators. Finally, this study involved phar-
macy students from one University and innovative com-
munity pharmacists from the upper Midwest and West,
thereby limiting its generalizability.
CONCLUSION
TIMERwas effective in increasing the number of tool-
related DRPs found by pharmacists and by pharmacy stu-
dents in hypothetical patient cases. TIMERmay help phar-
macists provide required MTM services for older adults.
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